aVLFA0822p Farmakologie II - přednáška

Lékařská fakulta
jaro 2019
Rozsah
2/0/0. 30. 4 kr. Ukončení: zk.
Vyučující
Mgr. Petra Amchová, Ph.D. (přednášející)
doc. RNDr. Ladislava Bartošová, Ph.D. (přednášející)
doc. MUDr. Regina Demlová, Ph.D. (přednášející)
doc. PharmDr. Jan Juřica, Ph.D. (přednášející)
Mgr. Jana Kubátová, Ph.D. (přednášející)
doc. Mgr. MVDr. Leoš Landa, Ph.D. (přednášející)
MUDr. Jana Nováková, Ph.D. (přednášející)
PharmDr. Adriána Papiež, Ph.D. (přednášející)
MUDr. Jana Pistovčáková, Ph.D. (přednášející)
doc. PharmDr. Jana Rudá, Ph.D. (přednášející)
PharmDr. Jitka Rychlíčková, Ph.D. (přednášející)
Mgr. Barbora Říhová, Ph.D. (přednášející)
PharmDr. Lenka Součková, Ph.D. (přednášející)
doc. PharmDr. Ondřej Zendulka, Ph.D. (přednášející)
Renata Bláblová (pomocník)
Květoslava Sedlářová (pomocník)
Mgr. Kateřina Nebeská (náhr. zkoušející)
Mgr. Kristýna Nosková, Ph.D. (náhr. zkoušející)
MUDr. Filip Šiška (náhr. zkoušející)
Garance
doc. MUDr. Regina Demlová, Ph.D.
Farmakologický ústav – Teoretická pracoviště – Lékařská fakulta
Kontaktní osoba: doc. PharmDr. Ondřej Zendulka, Ph.D.
Dodavatelské pracoviště: Farmakologický ústav – Teoretická pracoviště – Lékařská fakulta
Rozvrh
Út 12. 3. až Pá 31. 5. Út 17:00–18:40 KOM 200, Po 18. 2. až Út 5. 3. Út 17:00–18:40 B22/116 aula
Předpoklady
aVLFA0721p Farmakologie I - přednáška && aVLPF0622p Patologická fyziol. II - př
Omezení zápisu do předmětu
Předmět je nabízen i studentům mimo mateřské obory.
Mateřské obory/plány
Cíle předmětu
The aim of the course is to acquiant the students with drugs from selected pharmacotherapeutic groups.
Výstupy z učení
At the end of the course student should be able choose and prescribe suitable drug for the patient with known indicication. The selection will be made with respect to all factors influencing drug safety and efficacy.
Osnova

  • VLFA08222p - Pharmacology II lecture

    General medicine

    Spring semester 2019

  • 19. 2. 2019
  • 1. INTRODUCTION TO PSYCHOPHARMACOLOGY, ANTIPSYCHOTICS, ANTIPARKINSONICS
  • Lecture content: History and classification of psychotropic substances. Antipsychotics, antiparkinsonics – basic pharmacological review.
  • 26. 2. 2019
  • 2. ANXIOLYTICS, HYPNOSEDATIVES, ANTICONVULSANTS
  • Lecture content: Anxiolytics, hypnosedatives, anticonvulsants - basic pharmacological review. The possibilities of modulation of GABAergic neurotransmission.
  • 5. 3. 2019
  • 3. ANTIDEPRESSANTS
  • Lecture content: Pharmacological review of antidepressants and their clinical use.
  • 12. 3. 2019
  • 4. DRUGS OF DISEASES WITH CHRONIC PULMONARY OBSTRUCTION, H 1-ANTIHISTAMINES.
  • Lecture content: Effects of histamine and how to antagonize it. Classification of H 1 antihistamines. Pharmacological review of drugs used in the therapy of diseases with chronic pulmonary obstruction.
  • 19. 3. 2019
  • 5. ANTIANGIAL DRUGS
  • Lecture content: Pharmacological review of drugs used in the treatment of both acute and chronic ischemic heart disease.
  • 26. 3. 2019
  • 6. ANTIHYPERTENSIVES
  • Lecture content: Pharmacological review of antihypertensives with special focus on drugs interfering with RAAS and diuretics. Second-line antihypertensives.
  • 2. 4. 2019
  • 7. DRUGS OF HEART FAILURE, ANTIARRHYTHMICS
  • Lecture content: Review of drugs used in the therapy of acute and chronic heart failure, Pharmacological review of antiarrhytmics.
  • 9. 4. 2019
  • 8. DRUGS INFLUENCING HEMOSTASIS
  • Lecture content: Pharmacological review of anticoagulants, antiplatelets, fibrinolytics, and hemostatics.
  • 16. 4. 2019
  • 9. ANTI-INFECTIVES I - ANTIBIOTICS
  • Lecture content: Introduction/principles of ATB therapy, modes of resistance, pharmacological review of single groups of ATBs.
  • 23. 4. 2019
  • 10. ANTI-INFECTIVES II – ANTIMYCOTICS AND ANTIVIRALS
  • Lecture content: Systemic and local antimycotics; antiherpetics; pharmacotherapy of influenza; antiretrovirals; therapy of RSV and viral hepatitis – pharmacological review.
  • 30. 4. 2019
  • 11. PHARMACOLOGY OF GIT – ULCER DISEASE, ANTIEMETICS, ANTIDIARRHEALS AND LAXATIVES
  • Lecture content: Pharmacological review of drugs acting on GIT.
  • 7. 5. 2019
  • 12. CYTOSTATICS AND TARGETED THERAPY IN ONCOLOGY
  • Lecture content: Introduction. Classification of cytostatics according to their mechanisms of action. Mechanisms of resistance to anticancer drugs. Role of single nucleotide polymorphisms (SNPs) and TDM in oncology. Basic pharmacological properties of selected cytostatics. Principles of targeted therapy in oncology. Monoclonal antibodies. Protein kinase inhibitors. Targeted immunotherapy.
  • 14. 5. 2019
  • 13. THERAPY OF INTOXICATIONS
  • Lecture content: Review of most common intoxications and their symptomatology.. General principles of poisoning management. Specific antidotes in poisoning therapy.
  • 21. 5. 2019
  • 14. DRUG-DRUG INTERACTIONS
  • Lecture content: Classification of drug-drug interaction, evaluation of clinical relevance and seriousness oc drug interactions, management of drug interactions, possibilities of drug interactions monitoring, case-reports.
  • 28. 5. 2019
  • 15. PHYTOPHARMACOLOGY AND PHARMACOGNOSY
  • Lecture content: Natural sources of medicines, selected groups of herbal active components, herbal preparations. The most common herbal poisons.
Literatura
    povinná literatura
  • RANG, H. P., James RITTER, R. J. FLOWER a Graeme HENDERSON. Rang & Dale's pharmacology. Eighth edition. [Edinburgh]: Churchill Livingstone, 2016, xv, 760. ISBN 9780702053627. info
    doporučená literatura
  • WHALEN, Karen. Pharmacology. Edited by Richard Finkel - Thomas A. Panavelil. 6th ed. Philadelphia, Pa.: Lippincott Williams & Wilkins, 2015, xi, 664. ISBN 9781451191776. info
    neurčeno
  • Study materials in the IS, course aVLFA0822p and aVLFA0822c
  • Exam question outlines in the IS
Výukové metody
lectures
Metody hodnocení
The final evaluation of the course contains also results of the tests from practicals of both semesters and results of colloquium test.

The final mark is calculated by following method:

Relative weight of the mark from tests: 40 %
Relative weight of the mark from oral exam: 60 %

To calculate mark from the tests the following method will be used:
The summary score from all tests in courses VLFA07212c, VLFA07212p, VLFA08222c, and VLFA08222p is 230 pts. Minimum to pass through the course to the oral exam is 116 pts.
A = 191-230 pts
B = 171-190 pts
C = 153-170 pts
D = 135-152 pts
E = 117-134 pts
F = less than 116 pts

To calculate mark from the oral examthe following method will be used:
Three different questions are chosen by students from three different sets of questions at oral exam. Moreover the student answers additional questions of examinator. Each of drawn questions has relative weight of 20 % and the additional questions relative weight of 40% in the final mark of the oral exam. When student is evaluated by F for any of these questions the overall rating of oral exam is also F.

In case of success with the ROPOT test, but classification F from the oral part, students enter the oral part next time and for the final mark the score from the last ROPOT attempt is u
Vyučovací jazyk
Angličtina
Informace učitele

General pharmacology:


1. Pharmacology, sub-branches, origin of drugs, drug names.
2. Types of pharmacotherapy, rules of rational and safe phramacotherapy. The question of drug misuse.
3. Preclinical and clinical trials, stages.
4. Basic legislation related to drug use, Sources of information on drugs and medicinal products.
5. Solid and gaseous pharmaceutical drug dosage forms - overview and their influence on pharmacokinetics and pharmacodynamics.
6. Semi-solid and liquid pharmaceutical drug dosage forms - overview and their influence on pharmacokinetics and pharmacodynamics.
7. Routes of drug administration – overview, characteristics.
8. Drug absorption, presystemic elimination, drug bioavailability.
9. Drug distribution, volume of distribution, redistribution. General principles of drug movement through the body.
10. Drug elimination, processes of the first and zero order, drug accummulation.
11. Drug biotransformation – stages, examples.
12. Drug excretion (ways of excretion, possibilities of their influence).
13. Therapeutic monitoring of drugs (TDM).
14. Pharmacokinetics of single, repeated and continual drug administration.
15. Modes of drug action
16. Inhibition and induction of enzymes in pharmacokinetics and pharmacodynamics of drugs – examples.
17. Synergism and antagonism in drug effect (pharmacokinetics, pharmacodynamics).
18. Dose – response curves, types of doses, drug anamnesis, patient‘s adherence.
19. Adverse drug reactions (types, categories, examples).
20. Pharmacovigilance, drug safety.
21. Primary resistance of the patient to the treatment. Influence of repeated administration on drug efficacy - examples of tolerance and tachyphylaxis.
22. Factors influencing the drug effect – examples.
23. Pharmacotherapy in elderly, the influence of co-morbidities on drug effect, polypharmacy.
24. Pharmacotherapy in pediatric population, in breastfeeding women. Drugs influencing breast feeding.
25. Pharmacotherapy in pregnancy, drug teratogenicity.
26. Pharmacogenetics, influence of genetic polymorfisms on pharmacokinetics and pharmacodynamics of drugs.
27. Drug interactions - overview, examples.
28. Principles of biological treatment – classification, technology, examples of clinical use.

Special pharmacology:


1. Sympathomimetics - overview of single classes and their indications, examples of drugs
2. Sympatholytics - overview of single classes and their indications, examples of drugs
3. Cholinomimetics
4. Cholinolytics
5. Antispasmodics - GIT + UGT.
6. Glucocorticoids
7. Immunostimulants + immunosuppressants (except glucocorticoids)
8. Antidiabetics (except insulines)
9. Insulins
10. Sex hormones - contraception and HRT
11. Drugs targeting H-P axis and their indications (except contraception and HRT)
12. Uterotonics and tocolytics
13. Opioid analgesics
14. NSAIDs, non-opioid analgesics, antimigraine agents
15. Antiuratics, antirheumatics incl. DMARDs
16. General anesthetics
17. Local anesthetics
18. Muscle relaxants
19. Antipsychotics
20. Drugs of neurogenerative diseases (Parkinson’s disease; dementia)
21. Anticonvulsants
22. Nootropics, cognitives
23. Hypnosedatives, anxiolytics
24. Antidepressants - iMAO+SSRI+NDRI
25. Antidepressants - tricyclic, NASSA, MASSA, SARI, SNRI, NARI, SMS
26. Psychotomimetics, drugs used in ADHD
27. Antiasthmatics, drugs used in COPD
28. Antitussives, mucoactive drugs
29. H1 antihistamines
30. Hypolipidemics, anti-obesity drugs
31. Antihypertensives – drugs targeting RAAS
32. Antihypertensives – diuretics and aldosterone antagonists
33. Antihypertensives beta blockers + central antihypertensives
34. Antihypertensives - calcium channel blockers, α1 lytics
35. Antiangial agents
36. Antiarrhythmics
37. Drugs used in heart failure
38. Antiplatelet agents
39. Fibrinolytics, antifibrinolytics
40. Anticoagulants
41. Antianemics, hemostatics
42. Aminoglycosides
43. Principles of antibacterial therapy – overview, modes of action, resistance, MIC, MBC
44. Lincosamides, glycopeptides, polymyxins
45. Tetracyclines + related ATBs, amphenicoles
46. Cephalosporines, monobactams
47. Penicillins, carbapenems
48. Sulphonamides, nitrofurans and nitroimidazoles
49. Macrolides and related ATBs
50. Quinolones, antituberculotics
51. Antimycotics
52. Dermatologics – overview of classes, drugs and effects
53. Antivirotics
54. Antiemetic drugs, prokinetics, antivertigo drugs
55. Laxatives, antidiarrhoics, drugs of infectious diarrhoeas
56. Antiulcer agents, hepatoprotectives and drugs influencing the production and excretion of bile
57. Alkylating cytostatics and other drugs aiming on DNA in oncology
58. Biological treatment of autoimmune diseases
59. Targeted treatment in oncology
60. Antimetabolites + hormonal therapy in oncology
61. Drugs causing addiction
62. Drugs used in the treatment of addiction
63. General principles of drug poisoning, specific antidotes and their mechanisms of action
64. Drugs for inflammatory bowel disease
65. Drugs used in erectile dysfunction and BHP
66. Drugs used in osteoporosis, pharmacology of thyroid gland
67. Vitamins
68. Antiglaucomatics and cycloplegics

„Essential drugs“


1. adrenalin/noradrenalin
2. dobutamine
3. ephedrine/pseudoephedrine
4. phenylephrine
5. oxymetazoline
6. methyldopa
7. salbutamol
8. doxazosin
9. metoprolol
10. timolol
11. atropin
12. butylscopolamine
13. fenpiverine/pitofenon
14. pilocarpine
15. rivastigmine
16. physostigmine
17. solifenacin
18. dexametasone
19. prednisone
20. cyclosporine
21. interferons
22. methotrexate
23. metformin
24. glimepiride
25. sitagliptin
26. insulin lispro
27. insulin glargine
28. ethinylestradiol
29. cyproterone
30. tibolone
31. tamoxifen
32. hexoprenaline
33. oxytocin
34. levonorgestrel
35. paracetamol/ASA
36. ibuprofen/diclofenac
37. indometacin
38. nimesulide/meloxicam
39. buprenorphine
40. morphine/naloxone
41. sufentanil
42. tramadol
43. metamizole
44. allopurinol
45. sumatriptan
46. desflurane
47. propofol
48. ketamine
49. procaine/lidocaine
50. suxamethonium
51. prilocaine
52. haloperidol
53. olanzapine
54. aripiprazole
55. levodopa/carbidopa
56. diazepam
57. buspirone
58. piracetam/pyritinol
59. gabapentin/pregabalin
60. carbamazepine
61. valproic acid
62. zolpidem
63. midazolam
64. escitalopram
65. amitriptyline
66. mirtazapine
67. lithium
68. methylphenidate
69. acetylcysteine
70. codeine
71. butamirate
72. ipratropium-bromide
73. bisulepine/cetirizine
74. atorvastatine
75. fenofibrate
76. ezetimibe
77. isosorbid dinitrate/nitroglycerin
78. hydrochlorothiazide/indapamide
79. furosemid
80. spironolactone
81. amlodipin
82. perindopril
83. telmisartan
84. warfarin
85. enoxaparin
86. clopidogrel
87. dabigatran
88. rivaroxaban
89. alteplase
90. digoxin
91. amiodarone
92. verapamil
93. levosimendan
94. doxycycline
95. co-amoxicillin
96. phenoxymethylpenicillin
97. piperacillin
98. meropenem
99. cefuroxim
100. cotrimoxazol
101. clarithromycin
102. azithromycin
103. gentamicin
104. ciprofloxacin
105. vancomycin
106. rifampicin
107. terbinafine
108. caspofungin
109. amphotericin B
110. fluconazole
111. acyclovir
112. zidovudine
113. isotretinoin
114. salicylic acid
115. ondansetron
116. moxastine
117. pantoprazol
118. famotidin
119. lactulose
120. aprepitant
121. metoclopramid
122. loperamide
123. betahistine
124. cinnarizine
125. cyclophosphamide
126. methotrexate
127. 5-fluorouracil
128. paclitaxel
129. doxorubicin
130. cisplatin
131. trastuzumab
132. imatinib
133. interferon alfa
134. nivolumab
135. methadone
136. buprenorphine
137. nalmefene
138. naltrexone
139. finasteride
140. sildenafil
141. ibandronic acid
Další komentáře
Studijní materiály
Předmět je vyučován každoročně.
Nachází se v prerekvizitách jiných předmětů

Zobrazit další předměty

Předmět je zařazen také v obdobích jaro 2018, jaro 2020, jaro 2021, jaro 2022, jaro 2023, jaro 2024, jaro 2025.